- Home
- EDIT vs SABA Comparison
EDIT vs SABA Comparison
Compare EDIT & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDIT | SABA |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 225.6M |
| IPO Year | 2016 | 1994 |
Fundamental Metrics
Financial Performance| Metric | EDIT | SABA |
|---|---|---|
| Price | $2.64 | $8.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.92 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 117.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | ★ 37.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,937,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.64 | N/A |
| 52 Week Low | $0.91 | $7.72 |
| 52 Week High | $4.54 | $9.46 |
Technical Indicators
Market Signals| Indicator | EDIT | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 67.16 | 51.08 |
| Support Level | $2.42 | $7.97 |
| Resistance Level | $2.76 | $8.27 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 87.56 | 54.31 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.